Treatment with atogepant, also known as Aquipta

The preparation

Aquipta is specifically developed to prevent migraines and is approved for adults who have at least 4 migraine days per month.

Mechanism of action

It is known that CGRP (calcitonin gene-related peptide), which is produced in our nervous system, plays an active role in a migraine attack.

Atogepant, the active ingredient in Aquipta, is believed to work by blocking the activity of the CGRP molecule in the brain. This can reduce the frequency and severity of your migraine attacks.

Aquipta has a half-life of approximately 11 hours, meaning that once you stop taking Aquipta, it is cleared from your body within a few days.

Side effects

Approximately 1-10% experience nausea, constipation, fatigue, decreased appetite, and weight loss.

If you experience side effects not mentioned here, please let us know so we can report them to the Danish Medicines Agency.

Precautions

Aquipta must not be used by pregnant or breastfeeding women.

You must stop taking Aquipta at least 5 days before trying to conceive.

Aquipta should not be used if you have severely impaired liver function.

In case of impaired kidney function, the dose of Aquipta is reduced to 10 mg

Before starting treatment

Before you start treatment with Aquipta, you must have a blood test to check your liver and kidney values

What is the dosage?

You should take one 60 mg tablet once daily. However, if you have impaired kidney function, you must only take one 10 mg tablet once daily.

How should Aquipta be taken?

Aquipta can be taken in the morning or evening. The tablets can be swallowed whole, chewed, or crushed and can be taken with or without food.

If you miss a dose, take it as soon as possible. If you have missed a dose for an entire day, skip it and take your next dose as scheduled.